Australia markets open in 5 hours 34 minutes

    -42.80 (-0.53%)

    +0.0075 (+1.13%)
  • ASX 200

    -39.90 (-0.51%)
  • OIL

    +0.61 (+0.78%)
  • GOLD

    +18.10 (+0.78%)
  • Bitcoin AUD

    +3,598.79 (+3.59%)
  • CMC Crypto 200

    +30.54 (+2.19%)

TFF Pharmaceuticals Third Quarter 2022 Earnings: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

TFF Pharmaceuticals (NASDAQ:TFFP) Third Quarter 2022 Results

Key Financial Results

  • Net loss: US$7.27m (loss narrowed by 16% from 3Q 2021).

  • US$0.29 loss per share (improved from US$0.34 loss in 3Q 2021).


All figures shown in the chart above are for the trailing 12 month (TTM) period

TFF Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 12% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with TFF Pharmaceuticals (at least 3 which are a bit unpleasant), and understanding these should be part of your investment process.


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here